EU5 physicians more frequently targeted NASH and/or associated comorbidities using antidiabetic agents associated with weight loss, e.g. glucagon-like peptide 1 agonists, whereas Middle Eastern physicians more commonly used statins, pioglitazone, and vitamin E. Here, GCG is linked to metabolic dysfunction-associated steatohepatitis.